Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabienne Thomas

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 9, 2023
Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiencyMarie-Christine Etienne-Grimaldi, Nicolas Pallet, Valérie Boige, et al.
Clinical Pharmacokinetics|April 25, 2020
Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid MalignanciesFanny Gallais, Loïc Ysebaert, Fabien Despas, et al.
Journal for Immunotherapy of Cancer|September 24, 2024
Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancersKhaldoun Gharzeddine, Cristina Gonzalez Prieto, Marie Malier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinomaBenjamin R Tan, Fabienne Thomas, Robert J Myerson, et al.
Cancer Chemotherapy and Pharmacology|June 13, 2020
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidineXandra García-González, Bartosz Kaczmarczyk, Judith Abarca-Zabalía, et al.
Clinical Pharmacokinetics|March 9, 2026
Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors MethodsFélicien Le Louedec, Laura Morvan, Loïc Mourey, et al.
Cancer Management and Research|October 24, 2018
Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase <i>(DPYD)</i> geneXandra García-González, Sara López-Tarruella, María Isabel García, et al.
Pharmaceutical Research|July 18, 2020
Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell TumorsSotheara Moeung, Christine Chevreau, Sabrina Marsili, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 24, 2024
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patientsAlicja Puszkiel, Florence Dalenc, Naïma Tafzi, et al.
British Journal of Clinical Pharmacology|February 28, 2019
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patientsFélicien Le Louedec, Catherine Alix-Panabières, Thierry Lafont, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|January 9, 2023
Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiencyMarie-Christine Etienne-Grimaldi, Nicolas Pallet, Valérie Boige, et al.
Clinical Pharmacokinetics|April 25, 2020
Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid MalignanciesFanny Gallais, Loïc Ysebaert, Fabien Despas, et al.
Journal for Immunotherapy of Cancer|September 24, 2024
Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancersKhaldoun Gharzeddine, Cristina Gonzalez Prieto, Marie Malier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinomaBenjamin R Tan, Fabienne Thomas, Robert J Myerson, et al.
Cancer Chemotherapy and Pharmacology|June 13, 2020
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidineXandra García-González, Bartosz Kaczmarczyk, Judith Abarca-Zabalía, et al.
Clinical Pharmacokinetics|March 9, 2026
Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors MethodsFélicien Le Louedec, Laura Morvan, Loïc Mourey, et al.
Cancer Management and Research|October 24, 2018
Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase <i>(DPYD)</i> geneXandra García-González, Sara López-Tarruella, María Isabel García, et al.
Pharmaceutical Research|July 18, 2020
Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell TumorsSotheara Moeung, Christine Chevreau, Sabrina Marsili, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 24, 2024
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patientsAlicja Puszkiel, Florence Dalenc, Naïma Tafzi, et al.
British Journal of Clinical Pharmacology|February 28, 2019
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patientsFélicien Le Louedec, Catherine Alix-Panabières, Thierry Lafont, et al.
Pageof 9